Developer docs
API playgroundTry for free, no card

Search company profiles

MOMM Diagnostics

Full company profile

uuid0004zqc

Namestring
MOMM Diagnostics
Legal namestring
MOMM Diagnostics GmbH
Company typeenum
Private
Founded yearint
2018
Descriptiontext

MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup founded in 2018 that is developing a rapid in-vitro diagnostic test for the early detection of preeclampsia. The company's platform-plus-assay architecture consists of the eFlow, a patented compact electrochemical biosensor reader designed for near-patient settings, and the préXclude, a cartridge-based rapid test that quantifies the established preeclampsia biomarkers sFlt-1 and PlGF. The company claims over 95% accuracy in centralized lab assays and aims to deliver results in minutes from a simple fingerstick blood sample, targeting a gap left by current lab-based diagnostics that take days to return results for a condition affecting 5-8% of all pregnancies.

The company was co-founded through a partnership between US-based Avails Medical, Inc. and Swiss federal research institute Empa, and has since built additional research collaborations with FHNW School of Life Sciences, CSEM, and the University of Basel NanoScience. Its management team is led by PhD co-founder and CEO Mathias Wipf and PhD Director of R&D Christopher Wood, supported by PhD-level scientific, medical, and business advisors. The intended go-to-market is direct enterprise sales to healthcare providers — hospitals and prenatal care clinics — with secondary use cases in at-home testing for pregnant women and research applications for novel biomarker development.

The company is pre-revenue and pre-commercial: both eFlow and préXclude remain in the development phase and are not yet available for commercial use. The intended revenue model combines one-time hardware sales of the eFlow reader with recurring cartridge consumables for préXclude tests, supplemented by future professional services for biomarker testing. To date, funding has come almost entirely from non-dilutive sources, including Innosuisse grants, 5HT Digital Hub Chemistry Health, CE Switzerland, and the University of Basel, plus a 2018 Venture Kick seed and a $500,000 grant from the Bill & Melinda Gates Foundation awarded in October 2025. No venture capital or private equity rounds are disclosed.

Short descriptiontext

MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup developing the eFlow point-of-care diagnostic platform and the préXclude rapid preeclampsia test, which uses sFlt-1 and PlGF biomarkers to deliver lab-quality results in minutes from a fingerstick blood sample for healthcare providers, pregnant women, and researchers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
rapid diagnostic testing, preeclampsia detection, point-of-care diagnostics, biomarker measurement, electrochemical biosensors
Industry2 codes
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In-vitro diagnostics for preeclampsia
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1préXclude Test Kits
TypeOne Time License
Description

Revenue anticipated from sale of rapid preeclampsia test cartridges for the eFlow platform. Products are currently in development phase and not yet commercially available.

mommdiagnostics.com
2eFlow Platform Hardware
TypeHardware Sales
Description

Compact diagnostic reader device sales to healthcare providers for near-patient testing. Currently in development phase.

mommdiagnostics.com
3Biomarker Testing Services
TypeProfessional Services
Description

Future opportunity to offer novel biomarker testing on MOMM's eFlow platform to researchers and diagnostic providers.

mommdiagnostics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1préXclude
Description

Ground-breaking rapid preeclampsia test designed for the eFlow system - the fastest and most precise method for detecting preeclampsia in pregnant women. Utilizes biomarkers sFlt-1 and PlGF with over 95% accuracy.

mommdiagnostics.com
+1 more record
Core offering1 text field

MOMM Diagnostics develops an in-vitro diagnostic solution for the early detection of preeclampsia. Its offering centers on the préXclude rapid test cartridge — measuring the established biomarkers sFlt-1 and PlGF with reported accuracy above 95% in centralized lab assays — which runs on the company's patented eFlow compact reader platform. The combined product enables near-patient, fingerstick-based testing that returns results in minutes, intended for hospitals, clinics and at-home prenatal monitoring.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 95% accuracy rate in centralized lab assays
+2 more records
Product overview1 text field

MOMM Diagnostics offers a platform-plus-assay architecture consisting of the eFlow diagnostics platform and the préXclude rapid preeclampsia test. The eFlow is a compact, patented reader device designed for near-patient settings that delivers lab-quality sensitivity at point-of-care. The préXclude assay is a cartridge-based rapid diagnostic test that runs on the eFlow platform, utilizing established biomarkers (sFlt-1 and PlGF) to detect preeclampsia risk with over 95% accuracy, requiring only a fingerstick blood sample and delivering results in minutes. Both products are currently in the development phase.

Product and service2 records
1préXclude
CategoryRapid diagnostic test (in-vitro diagnostic cartridge)
Description

Rapid preeclampsia diagnostic test cartridge that runs on the eFlow reader. Measures the biomarkers sFlt-1 and PlGF from a simple fingerstick blood sample with reported accuracy above 95% in centralized lab assays and delivers results in minutes. Intended for near-patient use in hospitals, clinics and at-home prenatal monitoring.

2eFlow
CategoryDiagnostic hardware (point-of-care reader platform)
Description

Patented compact diagnostic reader platform designed for near-patient settings including clinics and at-home testing. Combines electrochemical biosensor technology with a compact, low-cost reader to deliver lab-based assay sensitivity at point-of-care with rapid results and minimal hands-on time and training required.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Co-founding partner of MOMM Diagnostics startup. Contributed to the establishment and technology foundation of the company alongside Empa research institute. This strategic partnership provided the foundational expertise for developing the eFlow diagnostics platform.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2018-01-01
Description

Swiss research institute that partnered with Avails Medical to co-found MOMM Diagnostics. Empa contributed research expertise enabling the development of groundbreaking eFlow technology and préXclude rapid preeclampsia test.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Research collaboration providing access to unique ecosystem for innovation. FHNW School of Life Sciences contributes expertise supporting MOMM's test menu expansion and technology development.

Strategic tierSupportingTypeStrategic or Co-development Partner
Description

Swiss research institution collaboration providing unique ecosystem for innovation. CSEM contributes technical expertise and infrastructure for MOMM Diagnostics technology development.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

MOMM Diagnostics

In-vitro diagnostics for preeclampsiamommdiagnostics.com

MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup developing the eFlow point-of-care diagnostic platform and the préXclude rapid preeclampsia test, which uses sFlt-1 and PlGF biomarkers to deliver lab-quality results in minutes from a fingerstick blood sample for healthcare providers, pregnant women, and researchers.

What MOMM Diagnostics does

MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup founded in 2018 that is developing a rapid in-vitro diagnostic test for the early detection of preeclampsia. The company's platform-plus-assay architecture consists of the eFlow, a patented compact electrochemical biosensor reader designed for near-patient settings, and the préXclude, a cartridge-based rapid test that quantifies the established preeclampsia biomarkers sFlt-1 and PlGF. The company claims over 95% accuracy in centralized lab assays and aims to deliver results in minutes from a simple fingerstick blood sample, targeting a gap left by current lab-based diagnostics that take days to return results for a condition affecting 5-8% of all pregnancies.

The company was co-founded through a partnership between US-based Avails Medical, Inc. and Swiss federal research institute Empa, and has since built additional research collaborations with FHNW School of Life Sciences, CSEM, and the University of Basel NanoScience. Its management team is led by PhD co-founder and CEO Mathias Wipf and PhD Director of R&D Christopher Wood, supported by PhD-level scientific, medical, and business advisors. The intended go-to-market is direct enterprise sales to healthcare providers — hospitals and prenatal care clinics — with secondary use cases in at-home testing for pregnant women and research applications for novel biomarker development.

The company is pre-revenue and pre-commercial: both eFlow and préXclude remain in the development phase and are not yet available for commercial use. The intended revenue model combines one-time hardware sales of the eFlow reader with recurring cartridge consumables for préXclude tests, supplemented by future professional services for biomarker testing. To date, funding has come almost entirely from non-dilutive sources, including Innosuisse grants, 5HT Digital Hub Chemistry Health, CE Switzerland, and the University of Basel, plus a 2018 Venture Kick seed and a $500,000 grant from the Bill & Melinda Gates Foundation awarded in October 2025. No venture capital or private equity rounds are disclosed.

MOMM Diagnostics firmographics

Firmographics
Name
MOMM Diagnostics
Legal name
MOMM Diagnostics GmbH
Website
https://mommdiagnostics.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
1–10 employees
Short description
MOMM Diagnostics GmbH is a Basel-based Swiss medtech startup developing the eFlow point-of-care diagnostic platform and the préXclude rapid preeclampsia test, which uses sFlt-1 and PlGF biomarkers to deliver lab-quality results in minutes from a fingerstick blood sample for healthcare providers, pregnant women, and researchers.
Ownership category
akta.pro rank

MOMM Diagnostics industry classification

Industry
Product category
In-vitro diagnostics for preeclampsia
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHAAAI
Genetic, Cytogenetic & Prenatal Screening IVD
Healthcare & Life Sciences/Medical Devices & Diagnostics/In Vitro Diagnostics (IVD) & Laboratory Diagnostics

Keywords

  • Rapid diagnostic testing
  • Preeclampsia detection
  • Point-of-care diagnostics
  • Biomarker measurement
  • Electrochemical biosensors

Where MOMM Diagnostics is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

MOMM Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. préXclude Test Kits: Revenue anticipated from sale of rapid preeclampsia test cartridges for the eFlow platform. Products are currently in development phase and not yet commercially available.
  2. eFlow Platform Hardware: Compact diagnostic reader device sales to healthcare providers for near-patient testing. Currently in development phase.
  3. Biomarker Testing Services: Future opportunity to offer novel biomarker testing on MOMM's eFlow platform to researchers and diagnostic providers.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

MOMM Diagnostics product offering

Product offering

Core offering

MOMM Diagnostics develops an in-vitro diagnostic solution for the early detection of preeclampsia. Its offering centers on the préXclude rapid test cartridge — measuring the established biomarkers sFlt-1 and PlGF with reported accuracy above 95% in centralized lab assays — which runs on the company's patented eFlow compact reader platform. The combined product enables near-patient, fingerstick-based testing that returns results in minutes, intended for hospitals, clinics and at-home prenatal monitoring.

Product overview

MOMM Diagnostics offers a platform-plus-assay architecture consisting of the eFlow diagnostics platform and the préXclude rapid preeclampsia test. The eFlow is a compact, patented reader device designed for near-patient settings that delivers lab-quality sensitivity at point-of-care. The préXclude assay is a cartridge-based rapid diagnostic test that runs on the eFlow platform, utilizing established biomarkers (sFlt-1 and PlGF) to detect preeclampsia risk with over 95% accuracy, requiring only a fingerstick blood sample and delivering results in minutes. Both products are currently in the development phase.

Differentiator

Problem solved

Functional benefit

Brands

  • préXclude: Ground-breaking rapid preeclampsia test designed for the eFlow system - the fastest and most precise method for detecting preeclampsia in pregnant women. Utilizes biomarkers sFlt-1 and PlGF with over 95% accuracy.
  • eFlow

Products and services

  • préXclude Rapid preeclampsia diagnostic test cartridge that runs on the eFlow reader. Measures the biomarkers sFlt-1 and PlGF from a simple fingerstick blood sample with reported accuracy above 95% in centralized lab assays and delivers results in minutes. Intended for near-patient use in hospitals, clinics and at-home prenatal monitoring.
  • eFlow Patented compact diagnostic reader platform designed for near-patient settings including clinics and at-home testing. Combines electrochemical biosensor technology with a compact, low-cost reader to deliver lab-based assay sensitivity at point-of-care with rapid results and minimal hands-on time and training required.

Quantifiable outcome

  • Over 95% accuracy rate in centralized lab assays
  • +2 more outcomes

Companies that use MOMM Diagnostics

Customer profile

Segments3 records

Ideal customer profiles2 records

MOMM Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

MOMM Diagnostics partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and supporting.

  • Avails Medical, Inc.coreStrategic or Co-development Partner · 1 January 2018Co-founding partner of MOMM Diagnostics startup. Contributed to the establishment and technology foundation of the company alongside Empa research institute. This strategic partnership provided the foundational expertise for developing the eFlow diagnostics platform.
  • Empa (Swiss Federal Laboratories for Materials Science and Technology)coreStrategic or Co-development Partner · 1 January 2018Swiss research institute that partnered with Avails Medical to co-found MOMM Diagnostics. Empa contributed research expertise enabling the development of groundbreaking eFlow technology and préXclude rapid preeclampsia test.
  • FHNW School of Life SciencessupportingStrategic or Co-development PartnerResearch collaboration providing access to unique ecosystem for innovation. FHNW School of Life Sciences contributes expertise supporting MOMM's test menu expansion and technology development.
  • CSEM (Swiss Center for Electronics and Microtechnology)supportingStrategic or Co-development PartnerSwiss research institution collaboration providing unique ecosystem for innovation. CSEM contributes technical expertise and infrastructure for MOMM Diagnostics technology development.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

MOMM Diagnostics competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

MOMM Diagnostics social profiles

Digital presence

MOMM Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

MOMM Diagnostics leadership team

Management profile

Number of profiles

Profiles5 records

MOMM Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

MOMM Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MOMM Diagnostics

What does MOMM Diagnostics do?

MOMM Diagnostics develops an in-vitro diagnostic solution for the early detection of preeclampsia. Its offering centers on the préXclude rapid test cartridge — measuring the established biomarkers sFlt-1 and PlGF with reported accuracy above 95% in centralized lab assays — which runs on the company's patented eFlow compact reader platform. The combined product enables near-patient, fingerstick-based testing that returns results in minutes, intended for hospitals, clinics and at-home prenatal monitoring.

Is MOMM Diagnostics a public or private company?

MOMM Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was MOMM Diagnostics founded?

MOMM Diagnostics was founded in 2018. It employs 1 to 10 people.

Where is MOMM Diagnostics based?

MOMM Diagnostics is headquartered in Basel, Switzerland, in the Europe region.

How does MOMM Diagnostics make money?

Three revenue lines are on record. préXclude Test Kits are the primary driver. The others are eFlow Platform Hardware and biomarker Testing Services.

Does MOMM Diagnostics have an API?

No public API is recorded for MOMM Diagnostics.

What industry is MOMM Diagnostics in?

MOMM Diagnostics's product category is In-vitro diagnostics for preeclampsia. Its primary akta.pro industry code is HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection), with a secondary code of HLAHAAAI, Genetic, Cytogenetic & Prenatal Screening IVD. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals